Feedback / Questions
Ii-Key Peptide-based Covid-19 vaccine - Shandong Academy of Sciences, Generex
http://www.globenewswire.com/news-release/2020/11/23/2131844/0/en/Generex-and-NuGenerex-Immuno-Oncology-Ii-Key-SARS-CoV-2-Vaccine-Partner-Bintai-Kinden-Executes-its-Exclusive-Distribution-Licensing-Option-for-Australia-and-New-Zealand.html
Nov 23, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next